
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics Inc is developing TH103, a novel anti-VEGF drug that demonstrates superior retinal retention compared to existing treatments like Eylea, suggesting enhanced durability for patient outcomes. The company’s promising preclinical findings, including the complete inhibition of VEGF-induced endothelial cell proliferation, underscore the potential for TH103 to outperform current therapies in treating prevalent retinal diseases. Additionally, the success of competing drugs like Vabysmo, which has generated over $4 billion in global sales, highlights the substantial market potential for innovative anti-VEGF therapies, positioning Kalaris Therapeutics favorably within this expanding arena.
Bears say
Kalaris Therapeutics Inc., being a development-stage biopharmaceutical company, faces substantial financial risks as it has yet to commercialize any products, which will require investment in infrastructure for the potential launch of its lead drug, TH103. The company is expected to continue incurring net losses until commercialization at best, with the protracted timelines for clinical development, regulatory approvals, and potential market competition further exacerbating its financial outlook. Additionally, Kalaris has no revenue-generating products and has accumulated significant losses since its inception, contributing to a negative perspective on its financial viability.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares